Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares of Stock

by · The Cerbat Gem

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $156,827.06. Following the completion of the transaction, the insider owned 1,111,130 shares of the company’s stock, valued at approximately $10,455,733.30. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

  • On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $141,494.34.
  • On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66.

Xeris Biopharma Price Performance

Xeris Biopharma stock traded down $0.17 during mid-day trading on Friday, hitting $9.08. The stock had a trading volume of 1,375,716 shares, compared to its average volume of 1,988,684. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.33. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a market capitalization of $1.66 billion, a P/E ratio of -82.55 and a beta of 0.53. The firm’s 50 day moving average is $8.45 and its 200 day moving average is $7.29.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC bought a new stake in shares of Xeris Biopharma in the 2nd quarter worth about $74,000. Allworth Financial LP lifted its holdings in shares of Xeris Biopharma by 86.4% in the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock valued at $34,000 after acquiring an additional 2,000 shares during the last quarter. Allianz Asset Management GmbH bought a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $314,000. Corient Private Wealth LP purchased a new position in Xeris Biopharma in the second quarter worth about $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Xeris Biopharma in the second quarter worth about $89,000. Institutional investors own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on XERS shares. Leerink Partners upped their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Barclays boosted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Finally, Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma presently has an average rating of “Hold” and a consensus price target of $12.80.

Check Out Our Latest Stock Report on Xeris Biopharma

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.

Read More